Evidence map›Paper›PMID 28676846›Full record

ArticleFrontiers in cellular and infection microbiology2017

Inactivation of the Thymidylate Synthase

Irene Rodríguez-Arce, Sara Martí, Begoña Euba, Ariadna Fernández-Calvet, Javier Moleres, Nahikari López-López, Montserrat Barberán, José Ramos-Vivas, Fe Tubau, Carmen Losa and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Case Report: Whole-Genome Sequencing of Serially CollectedFrontiers in cellular and infection microbiology · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Irene Rodríguez-ArceInstituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas-Universidad Pública Navarra-GobiernoNavarra, Spain.
Sara MartíCentro de Investigación Biomédica en Red de Enfermedades RespiratoriasMadrid, Spain.
Begoña EubaInstituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas-Universidad Pública Navarra-GobiernoNavarra, Spain.
Ariadna Fernández-CalvetInstituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas-Universidad Pública Navarra-GobiernoNavarra, Spain.
Javier MoleresInstituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas-Universidad Pública Navarra-GobiernoNavarra, Spain.
Nahikari López-LópezInstituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas-Universidad Pública Navarra-GobiernoNavarra, Spain.
Montserrat BarberánFacultad de Veterinaria, Universidad de ZaragozaZaragoza, Spain.
José Ramos-VivasServicio Microbiología, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de ValdecillaSantander, Spain.
Fe TubauCentro de Investigación Biomédica en Red de Enfermedades RespiratoriasMadrid, Spain.
Carmen LosaServicio de Microbiología, Clínica Universidad de NavarraNavarra, Spain.
Carmen ArdanuyCentro de Investigación Biomédica en Red de Enfermedades RespiratoriasMadrid, Spain.
José LeivaServicio de Microbiología, Clínica Universidad de NavarraNavarra, Spain.
José E YusteCentro de Investigación Biomédica en Red de Enfermedades RespiratoriasMadrid, Spain.
Junkal GarmendiaInstituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas-Universidad Pública Navarra-GobiernoNavarra, Spain.
Universidad Publica de Navarra · ESClinica Universidad de Navarra · ESConsejo Superior de Investigaciones Científicas · ESAgrobiotechnology Institute · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstituto de Salud Carlos III · ESRed Espanola de Investigacion en Patologia Infecciosa · ESUniversidad de Zaragoza · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibacterial treatment with cotrimoxazol (TxS), a combination of trimethoprim and sulfamethoxazole, generates resistance by, among others, acquisition of thymidine auxotrophy associated with mutations in the thymidylate synthase gene

Indexed as

A549 CellsAnimalsAnti-Bacterial AgentsBacterial ProteinsCell Line, TumorDNA, BacterialDrug Resistance, MicrobialFemaleGenes, BacterialHaemophilus InfectionsHaemophilus influenzaeHost-Pathogen InteractionsHumansInterleukin-8LungMiceAnti-Bacterial AgentsBacterial ProteinsDNA, BacterialInterleukin-8SulfamethoxazoleThymidineThymidylate SynthaseTrimethoprimTrimethoprim, Sulfamethoxazole Drug Combinationairway infectionantibiotic resistancebacterial morphologyHaemophilus influenzaethymidine auxotrophythymidine uptakethymidylate synthase

Identifiers

PMID28676846
PMCPMC5476696
OpenAlexW2654428937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.